Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Moore to follow Cummins and Westbrook out of Cyberonics?:

This article was originally published in Clinica

Executive Summary

A major shareholder in vagus nerve stimulation device make Cyberonics (Houston, Texas) has demanded the removal of Kevin Moore as director, and is seeking his return of fees and stock options. Metropolitan Capital Advisors (MCA) has given the company ten days to take the action against Mr Moore, who, it maintains, was not lawfully a member of the board, having not stood for election at the company's 2004 and 2005 AGM. MCA representatives also criticised the appointment of Tony Coelho as chairman (see Clinica No 1233, p 17), saying he had a role in the granting of options, with "serious consequences for Cyberonics".

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts